» Articles » PMID: 9333053

Molecular Biological Characterization of an Azole-resistant Candida Glabrata Isolate

Overview
Specialty Pharmacology
Date 1997 Oct 23
PMID 9333053
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Two isolates of Candida glabrata, one susceptible and one resistant to azole antifungals, were previously shown to differ in quantity and activity of the cytochrome P-450 14alpha-lanosterol demethylase which is the target for azole antifungals. The resistant isolate also had a lower intracellular level of fluconazole, but not of ketoconazole or itraconazole, than the susceptible isolate. In the present study a 3.7-fold increase in the copy number of the CYP51 gene, encoding the 14alpha-lanosterol demethylase, was found. The amount of CYP51 mRNA transcript in the resistant isolate was eight times greater than it was in the susceptible isolate. Hybridization experiments on chromosomal blots indicated that this increase in copy number was due to duplication of the entire chromosome containing the CYP51 gene. The phenotypic instability of the resistant isolate was demonstrated genotypically: a gradual loss of the duplicated chromosome was seen in successive subcultures of the isolate in fluconazole-free medium and correlated with reversion to susceptibility. The greater abundance of the amplified chromosome induced pronounced differences in the protein patterns of the susceptible and revertant isolates versus that of the resistant isolate, as demonstrated by two-dimensional gel electrophoresis (2D-GE). Densitometry of the 2D-GE product indicated upregulation of at least 25 proteins and downregulation of at least 76 proteins in the resistant isolate.

Citing Articles

Multiple routes to fungicide resistance: Interaction of Cyp51 gene sequences, copy number and expression.

Arnold C, Meyers Hahn E, Whetten R, Chartrain L, Cheema J, Brown J Mol Plant Pathol. 2024; 25(9):e13498.

PMID: 39305021 PMC: 11415427. DOI: 10.1111/mpp.13498.


Drivers of diversification in fungal pathogen populations.

Murante D, Hogan D PLoS Pathog. 2024; 20(9):e1012430.

PMID: 39264909 PMC: 11392411. DOI: 10.1371/journal.ppat.1012430.


The rise and future of CRISPR-based approaches for high-throughput genomics.

Vercauteren S, Fiesack S, Maroc L, Verstraeten N, Dewachter L, Michiels J FEMS Microbiol Rev. 2024; 48(5).

PMID: 39085047 PMC: 11409895. DOI: 10.1093/femsre/fuae020.


Long-term stability of acquired drug resistance and resistance associated mutations in the fungal pathogen ().

Ksiezopolska E, Schikora-Tamarit M, Carlos Nunez-Rodriguez J, Gabaldon T Front Cell Infect Microbiol. 2024; 14:1416509.

PMID: 39077431 PMC: 11284152. DOI: 10.3389/fcimb.2024.1416509.


Functional genetic characterization of stress tolerance and biofilm formation in () via a novel CRISPR activation system.

Maroc L, Shaker H, Shapiro R mSphere. 2024; 9(2):e0076123.

PMID: 38265239 PMC: 10900893. DOI: 10.1128/msphere.00761-23.


References
1.
Hitchcock C . Resistance of Candida albicans to azole antifungal agents. Biochem Soc Trans. 1993; 21(4):1039-47. DOI: 10.1042/bst0211039. View

2.
Sakakibara J, Watanabe R, Kanai Y, Ono T . Molecular cloning and expression of rat squalene epoxidase. J Biol Chem. 1995; 270(1):17-20. DOI: 10.1074/jbc.270.1.17. View

3.
Vanden Bossche H, Marichal P, Odds F . Molecular mechanisms of drug resistance in fungi. Trends Microbiol. 1994; 2(10):393-400. DOI: 10.1016/0966-842x(94)90618-1. View

4.
Kelly S, Lamb D, Corran A, Baldwin B, Kelly D . Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol. Biochem Biophys Res Commun. 1995; 207(3):910-5. DOI: 10.1006/bbrc.1995.1272. View

5.
Kosuga K, Hata S, Osumi T, Sakakibara J, Ono T . Nucleotide sequence of a cDNA for mouse squalene epoxidase. Biochim Biophys Acta. 1995; 1260(3):345-8. DOI: 10.1016/0167-4781(94)00245-x. View